Spore.Bio
PrivateLast Round
Grant
Jan 8, 2026
Total Funding Raised
$31.3M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Spore.Bio operates in Healthcare & Life Sciences and is based in Paris. Its latest recorded funding round was a Grant round in January 2026.
Spore.Bio is a biotechnology company that has developed an AI-powered technology for real-time microbiology testing.
Sector
Healthcare & Life Sciences
Verticals
Biotech Equipment, Biotechnology, Quality Management
Business Model
B2B
Customer Profile
Hardware + Subscription, Subscription SaaS
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Spore.Bio Comparables
Compare Spore.Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Myriad Optics | 84% | |
| MantaBio | 76% | |
| Plair SA | 76% |
For institutional investors. Book with your work email.
Spore.Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jan 8, 2026 | ||||
| Series A | Feb 19, 2025 | ||||
| Pre Seed | Dec 12, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Spore.Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| LocalGlobe | Series A, Pre Seed |
| Singular | Series A |
| EmergingTech Ventures | Pre Seed |
| 1st Kind by Peugeot Family | Series A |
| Better Angle | Pre Seed |
| Phoenix Court Group | Series A, Pre Seed |
| No Label Ventures | Series A, Pre Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 104% MoM, reaching 20.6K.
- Jul 20, 2026
Open roles increased to 103, 3.6x the trailing average.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- has_revenueSep 2, 2026
Spore reaches $20.2M in revenue in 2025.
For institutional investors. Book with your work email.
Spore.Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Spore.Bio's valuation, stock price, and market status.
Is Spore.Bio a public or private company?
Spore.Bio is a private company.
What is the current stock price of Spore.Bio?
Spore.Bio is a private company, so its shares have no public market price. Caplight tracks Spore.Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Spore.Bio worth (valuation)?
Valuation information for Spore.Bio is not publicly available.
Can I buy Spore.Bio stock?
Spore.Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Spore.Bio's last funding round?
Spore.Bio's most recent funding round was Grant on January 8, 2026.
Who are the main investors in Spore.Bio?
Key investors in Spore.Bio include LocalGlobe, Singular, Phoenix Court Group, Google.org.
Will Spore.Bio IPO soon?
No public IPO plans have been announced for Spore.Bio.
How can I track Spore.Bio secondary market activity?
Caplight tracks bids, offers, and trades in Spore.Bio's shares on secondary markets.